These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
603 related articles for article (PubMed ID: 10871299)
21. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747 [TBL] [Abstract][Full Text] [Related]
22. Current St John's wort research from mode of action to clinical efficacy. Müller WE Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057 [TBL] [Abstract][Full Text] [Related]
23. Simultaneous determination of total hypericin and hyperforin in St. John's wort extracts by HPLC with electrochemical detection. Rückert U; Likussar W; Michelitsch A Phytochem Anal; 2007; 18(3):204-8. PubMed ID: 17500362 [TBL] [Abstract][Full Text] [Related]
24. St. John's wort. Lawvere S; Mahoney MC Am Fam Physician; 2005 Dec; 72(11):2249-54. PubMed ID: 16342849 [TBL] [Abstract][Full Text] [Related]
25. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug? Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950 [TBL] [Abstract][Full Text] [Related]
26. Hyperforin as a possible antidepressant component of hypericum extracts. Chatterjee SS; Bhattacharya SK; Wonnemann M; Singer A; Müller WE Life Sci; 1998; 63(6):499-510. PubMed ID: 9718074 [TBL] [Abstract][Full Text] [Related]
27. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Moore LB; Goodwin B; Jones SA; Wisely GB; Serabjit-Singh CJ; Willson TM; Collins JL; Kliewer SA Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7500-2. PubMed ID: 10852961 [TBL] [Abstract][Full Text] [Related]
28. Effects of Hypericum perforatum extract and its main bioactive compounds on the cytotoxicity and expression of CYP1A2 and CYP2D6 in hepatic cells. Silva SM; Martinho A; Moreno I; Silvestre S; Granadeiro LB; Alves G; Duarte AP; Domingues F; Gallardo E Life Sci; 2016 Jan; 144():30-6. PubMed ID: 26612349 [TBL] [Abstract][Full Text] [Related]
29. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility. Capasso R; Borrelli F; Montanaro V; Altieri V; Capasso F; Izzo AA J Urol; 2005 Jun; 173(6):2194-7. PubMed ID: 15879886 [TBL] [Abstract][Full Text] [Related]
30. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Schulz HU; Schürer M; Bässler D; Weiser D Arzneimittelforschung; 2005; 55(1):15-22. PubMed ID: 15727160 [TBL] [Abstract][Full Text] [Related]
31. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. Schulz HU; Schürer M; Bässler D; Weiser D Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501 [TBL] [Abstract][Full Text] [Related]
32. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Laakmann G; Schüle C; Baghai T; Kieser M Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():54-9. PubMed ID: 9684948 [TBL] [Abstract][Full Text] [Related]
33. Preserved pharmacological activity of hepatocytes-treated extracts of valerian and St. John's wort. Simmen U; Saladin C; Kaufmann P; Poddar M; Wallimann C; Schaffner W Planta Med; 2005 Jul; 71(7):592-8. PubMed ID: 16041642 [TBL] [Abstract][Full Text] [Related]
34. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse. Bray BJ; Brennan NJ; Perry NB; Menkes DB; Rosengren RJ Life Sci; 2002 Feb; 70(11):1325-35. PubMed ID: 11883710 [TBL] [Abstract][Full Text] [Related]
35. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790 [TBL] [Abstract][Full Text] [Related]
36. Determining hyperforin and hypericin content in eight brands of St. John's wort. de los Reyes GC; Koda RT Am J Health Syst Pharm; 2002 Mar; 59(6):545-7. PubMed ID: 11908248 [No Abstract] [Full Text] [Related]
37. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Wurglics M; Schubert-Zsilavecz M Clin Pharmacokinet; 2006; 45(5):449-68. PubMed ID: 16640452 [TBL] [Abstract][Full Text] [Related]
38. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. Ng QX; Venkatanarayanan N; Ho CY J Affect Disord; 2017 Mar; 210():211-221. PubMed ID: 28064110 [TBL] [Abstract][Full Text] [Related]
39. St. John's wort components and the brain: uptake, concentrations reached and the mechanisms underlying pharmacological effects. Caccia S; Gobbi M Curr Drug Metab; 2009 Nov; 10(9):1055-65. PubMed ID: 20214594 [TBL] [Abstract][Full Text] [Related]
40. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum). Peebles KA; Baker RK; Kurz EU; Schneider BJ; Kroll DJ Biochem Pharmacol; 2001 Oct; 62(8):1059-70. PubMed ID: 11597574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]